Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
NCT04136353Phase 3Active, not recruiting
- Sponsor
- University of Sydney
- Start
- Mar 2020
- Primary completion
- Jan 2028
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 3 trial of darolutamide in prostate cancer (PCa), sponsored by University of Sydney. Started Mar 2020; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04136353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04136353.